Zymeworks Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Zymeworks has been growing earnings at an average annual rate of 21.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 37.8% per year.
Belangrijke informatie
21.8%
Groei van de winst
28.8%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | 37.8% |
Rendement op eigen vermogen | -31.0% |
Nettomarge | -182.8% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 03Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook
Nov 01Zymeworks Approaching A Moment Of Truth With Zanidatamab
Sep 27Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week
Aug 07Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up
Jul 26Zymeworks: A Somewhat Complicated Story
Jul 09Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
Jun 12Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business
May 03Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Zymeworks And The Blue Falcon Elucidation
May 17Opbrengsten en kosten
Hoe Zymeworks geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 62 | -114 | 60 | 0 |
30 Jun 24 | 63 | -113 | 63 | 0 |
31 Mar 24 | 50 | -126 | 69 | 0 |
31 Dec 23 | 76 | -119 | 70 | 0 |
30 Sep 23 | 462 | 205 | 87 | 0 |
30 Jun 23 | 448 | 186 | 86 | 0 |
31 Mar 23 | 446 | 173 | 80 | 0 |
31 Dec 22 | 412 | 124 | 75 | 0 |
30 Sep 22 | 30 | -224 | 49 | 0 |
30 Jun 22 | 32 | -237 | 49 | 0 |
31 Mar 22 | 28 | -240 | 53 | 0 |
31 Dec 21 | 27 | -212 | 42 | 0 |
30 Sep 21 | 22 | -211 | 50 | 0 |
30 Jun 21 | 21 | -223 | 56 | 0 |
31 Mar 21 | 31 | -194 | 49 | 0 |
31 Dec 20 | 39 | -181 | 55 | 0 |
30 Sep 20 | 25 | -215 | 72 | 0 |
30 Jun 20 | 30 | -173 | 63 | 0 |
31 Mar 20 | 26 | -163 | 62 | 0 |
31 Dec 19 | 30 | -145 | 63 | 0 |
30 Sep 19 | 57 | -64 | 40 | 0 |
30 Jun 19 | 51 | -52 | 36 | 0 |
31 Mar 19 | 65 | -29 | 31 | 0 |
31 Dec 18 | 53 | -37 | 30 | 0 |
30 Sep 18 | 74 | -13 | 28 | 0 |
30 Jun 18 | 72 | -11 | 26 | 0 |
31 Mar 18 | 52 | -16 | 19 | 0 |
31 Dec 17 | 52 | -11 | 18 | 0 |
30 Sep 17 | 4 | -55 | 19 | 0 |
30 Jun 17 | 6 | -51 | 16 | 0 |
31 Mar 17 | 11 | -47 | 17 | 0 |
31 Dec 16 | 11 | -34 | 13 | 0 |
30 Sep 16 | 10 | -30 | 9 | 0 |
31 Dec 15 | 10 | -19 | 5 | 0 |
31 Dec 14 | 2 | -13 | 4 | 0 |
Kwaliteitswinsten: ZYME is currently unprofitable.
Groeiende winstmarge: ZYME is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ZYME is unprofitable, but has reduced losses over the past 5 years at a rate of 21.8% per year.
Versnelling van de groei: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: ZYME has a negative Return on Equity (-30.97%), as it is currently unprofitable.